Phase II study to evaluate the safety and the efficacy of CBD (Bortezomib, Cyclophosphamide, Dexamethasone) regimen for the patients with relapsed and/or refractory multiple myeloma
Phase 2
Recruiting
- Conditions
- relapsed and/or refractory multiple myeloma
- Registration Number
- JPRN-UMIN000003076
- Lead Sponsor
- ara Hospital Kinki University School Of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
performance status:3 and 4(excluding PS3 by bone pain and fracture)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety (neurotoxixty evaluated by FACT/GOG NTX ver. 4.0)
- Secondary Outcome Measures
Name Time Method response rate as efficacy (antitumor activity) time to response, response rate after 5 more cycles, progression free survival, overall survival